Skip to main content
. 2020 Dec 10;8:599389. doi: 10.3389/fcell.2020.599389

FIGURE 8.

FIGURE 8

Immunoblot analysis for the ratio of Bcl-2 to Bax in the hippocampus. The ratio of Bcl-2 to Bax is decreased after scopolamine treatment, but reversed by 0.01 and 0.03 mg/kg BPN14770 (A). Pre-treatment with H89 (B), sirtinol (C), or MK-2206 (D) prevented the therapeutic effects of BPN14770 on protein expression. Results are displayed as mean ± S.E.M. (n = 4–5 per group). ∗∗P < 0.01 and ∗∗∗P < 0.001 vs. vehicle-treated control group; ##P < 0.01 and ###P < 0.001 vs. vehicle-treated scopolamine group; $$P < 0.01 and $$$P < 0.001 vs. BPN-treated scopolamine group. Rol, rolipram; Sirt, sirtinol; and MK, MK-2206.